Not-So-Public-Relations: Drug Industry & Bioethics – is it casuistry or sophistry? Fri, 19 Dec 2003 Carl Elliott is a clear eyed academic who teaches bioethics at the University of Minnesota . He is currently a visiting associate professor at School of Social Sciences at the Institute for Advanced Study at Princeton….
Dr. Sanghavi provides us with a statistical reality-check by which to gauge for ourselves whether or not we should–or need not–take a octor’s advice about starting a medical treatment for a speculated risk–rather than evidence of illness.
Bbioethicists are seizing the opportunity to expand their own marketability. The UK publication, NATURE, reports about the latest bioethics gimmick that has sprung up in California– ‘dial-an-ethicist’—at the Stanford Center for Biomedical Ethics.
A must read article by Carl Elliott, MD, Ph.D in the Atlantic Monthly provides the best insight into how pharmaceutical drug reps operate and the milieu in which today’s physicians practice
Big Pharma by Jacky Law reveals that in essence, most of the pharmaceutical industry’s claims are false; it is not the drug, but the placebo effect whose potency deserves almost all of the credit for any health improvement:
The Columbia lecture was originally scheduled as a debate between David Healy, MD and James Coyne, PhD. The debate did not take place, and Dr. Coyne subsequently lectured in Rutgers the following week. The lecture covered the main points Dr. Coyne makes in the e-mail below. Dr. Healy’s response follows….
Conflict of Interest: Profits vs Safety Congressional Investigations US Senators Pharmaceutical industry holdings, 2004: http://www.consumerwatchdog.org/resources/SenPharma.pdf Oct 12: How Did the Vioxx Debacle Happen? USA Today / Lancet Oct 4: Op Ed: Psychiatry on the Ropes–WP / Evidence-based Psychiatry Oct 3: BBC PANORAMA TONIGHT – Taken on Trust – 13 years-Medical…
Dr. Carl Elliott's insightful essay in SLATE:: Why do drug companies want to give money to bioethicists in the first place? In the public relations business, this approach is called "third-party strategy."
Presented by Vera Hassner Sharav
14th Tri-Service Clinical Investigation Symposium
Sponsored by The U.S. Army Medical Department and The Henry M. Jackson Foundation for the Advancment of Military Medicine
The cornerstone of public trust in medical research is the integrity of academic institutions and the expectation that universities, which rely on public funding, have a responsibility to serve the public good. Financial conflicts of interest affect millions of American people – those who are subjects of clinical trials testing new drugs and those who are prescribed drugs after their approval.
CONFLICTS OF INTEREST Presented by Vera Hassner Sharav 14th TRI-SERVICE CLINICAL INVESTIGATION SYMPOSIUM Sponsored By THE U.S. ARMY MEDICAL DEPARTMENT And THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCMENT OF MILITARY MEDICINE May 5-7, 2002 The cornerstone of public trust in medical research is the integrity of academic institutions and…
July 25, 2001 Bioethics and Big Bucks – US NEWS In a July 14 infomail about the ethics of cloning, and bioethicist Glenn McGee’s letter of resignation from the “ethics advisory board” of Advanced Cell Technology, I asked: “how can bioethicists retain their professional integrity when they become servants of…
